Amneal gains FDA nod for launch of Revatio® & Amicar® tablets
Category: #health  By Mateen Dalal  Date: 2019-12-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Amneal gains FDA nod for launch of Revatio® & Amicar® tablets

Amneal Pharmaceuticals, Inc. has made some consistent ripples in the generics and specialty pharmaceutical industry. Recently, the company made headlines when it revealed attaining final approval from the U.S. FDA on its ANDA (Abbreviated New Drug Applications) for generic editions of Amicar® (aminocaproic acid) Tablets USP, 500 mg and Revatio® for Oral Suspension 10 mg/ml.

According to a statement, Chintu Patel, Co-CEO, Amneal, said that their company is delighted to introduce these new drugs to healthcare providers and patients. He claims that their firm’s diverse and large pipeline has managed to deliver 36 new generic items in 2019 across multiple dosage forms.

Reportedly, Amneal had earlier bagged the designation of Competitive Generic Therapy (CGT) from the FDA for the generic version of Amicar®. Considering its first approved application, the biotech has been offered 180 days of CGT exclusivity.

Prior to this news, Amneal was in limelight for the launch of the generic version of Invega® (paliperidone). The drug was introduced in extended-release tablets ranging from 1.5mg to 9mg.

Speaking of which, Patel said that the company is pleased to get an approval for the launch of the generic version of Invega. It marks as one of 15 complex drugs that the firm expects to launch over 24-month.

Moreover, with a varied lineup of over 170 products, the company hopes to progress these types of complex product approvals, which would further expand its portfolio. Also, such moves would allow patients to buy generic medicines at affordable prices, cites Patel.

For the record, Amneal Pharmaceuticals, Inc. is based in Bridgewater, New Jersey. It is an integrated pharmaceutical firm focused on manufacturing, developing and distributing branded, generic, and biosimilar products. Amneal has operations in Asia, North America and Europe, and is working on bringing high-quality medicines to patients primarily within the U.S.
 

Source Credit: https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-Announces-the-Approval-and-Launch-of-Generic-Revatio-for-Oral-Suspension-and-Generic-Amicar-Tablets/default.aspx

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

TCL forays into the smartphone industry with three new TLC devices
TCL forays into the smartphone industry with three new TLC devices
By Mateen Dalal

TCL Communication, a renowned Chinese telecommunication company, has reportedly announced the launch of a new series of smartphones under the company brand name. The TCL 10 series is set to be launched in Australia during the second quarter of 2020.&...

Gilead to donate 1.5M doses of remdesivir to treat COVID-19 patients
Gilead to donate 1.5M doses of remdesivir to treat COVID-19 patients
By Mateen Dalal

Gilead Sciences, Inc., an American biotechnology company, has recently announced its plan to donate 1.5 million doses of the investigational drug, remdesivir. These 1.5 million doses will be used for over 140,000 treatment courses among coronavirus i...

Tesla Model 3 outsells Dodge Charger & Ford Mustang in the U.S.
Tesla Model 3 outsells Dodge Charger & Ford Mustang in the U.S.
By Mateen Dalal

The Tesla Model 3, a four-door electric sedan developed by Tesla, has reportedly outsold other top selling cars such as Dodge Charger and Ford Mustang in the United States. Other comparable vehicles to the new model are a class or 3 below the Model 3...